ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
14.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 139 citations in OpenAlex.
- Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Genomic and transcriptomic correlates of deep prostate-specific antigen response in patients with metastatic androgen pathway modulation-sensitive prostate cancer.The oncologist · 2026Article
- Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis.Nature communications · 2026Article
- Development of High-Affinity CHD1 Chromodomain Inhibitors.Journal of medicinal chemistry · 2026Article
- Molecular insights for the tumor suppressor role of SPOP in prostate cancer.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).Clinical genitourinary cancer · 2026Article
- Comprehensive genomic landscape of metastatic hormone-sensitive prostate cancer in the Chinese population.World journal of surgical oncology · 2025Article
- Germline-Somatic Liaison Dictates Cancer Subtypes via de novo Steroid Biosynthesis.Cancer discovery · 2025Article
- Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey.Prostate cancer and prostatic diseases · 2025Review
- New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.EMBO molecular medicine · 2025Review
- CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer.Nature cancer · 2025Article
- Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma.The journal of pathology. Clinical research · 2025Article
- CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors.Nature cancer · 2025Article
- Novel Intraprostatic Magnetic Resonance-Guided Implantation of Multidrug-Eluting Microdevice for Testing of Systemic Therapy Agents In Situ: Proof of Concept in Intermediate-Risk and High-Risk Prostate Cancer.The Journal of urology · 2025Article
- Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling.Cell communication and signaling : CCS · 2024Review
- Metastatic hormone-naïve prostate cancer: a distinct biological entity.Trends in cancer · 2024Review
- Hyd/UBR5 defines a tumor suppressor pathway that links Polycomb repressive complex to regulated protein degradation in tissue growth control and tumorigenesis.Genes & development · 2024Article
- Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.European urology oncology · 2024Article
- The therapeutic potential of targeting the CHD protein family in cancer.Pharmacology & therapeutics · 2024Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 5 institutions in 6 countries.
Gunther Boysen *Institute of Cancer Research, London, United Kingdom.
Daniel N Rodrigues *Institute of Cancer Research, London, United Kingdom.
Pasquale RescignoProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
George SeedInstitute of Cancer Research, London, United Kingdom.
David DollingInstitute of Cancer Research, London, United Kingdom.
Ruth RiisnaesInstitute of Cancer Research, London, United Kingdom.
Mateus CrespoInstitute of Cancer Research, London, United Kingdom.
Zafeiris ZafeiriouProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Semini SumanasuriyaProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Diletta BianchiniProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Joanne HuntProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Deirdre MoloneyProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Raquel Perez-LopezVall D'Hebron Institute of Oncology, Barcelona, Spain.
Nina TunariuProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Susana MirandaInstitute of Cancer Research, London, United Kingdom.ORCID 0000-0002-5936-2706
Inês FigueiredoInstitute of Cancer Research, London, United Kingdom.
Ana FerreiraInstitute of Cancer Research, London, United Kingdom.
Rossitza ChristovaInstitute of Cancer Research, London, United Kingdom.
Veronica GilInstitute of Cancer Research, London, United Kingdom.
Sara AzizInstitute of Cancer Research, London, United Kingdom.
Claudia BertanInstitute of Cancer Research, London, United Kingdom.
Flavia M de OliveiraInstitute of Cancer Research, London, United Kingdom.ORCID 0000-0002-2939-4715
Mark AtkinInstitute of Cancer Research, London, United Kingdom.
Matthew ClarkeInstitute of Cancer Research, London, United Kingdom.
Jane GoodallInstitute of Cancer Research, London, United Kingdom.
Adam SharpInstitute of Cancer Research, London, United Kingdom.
Theresa MacDonaldSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Mark A RubinSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Wei YuanInstitute of Cancer Research, London, United Kingdom.
Christopher E BarbieriSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-0381-1947
Suzanne CarreiraInstitute of Cancer Research, London, United Kingdom.
Joaquin MateoVall D'Hebron Institute of Oncology, Barcelona, Spain.
Johann S de BonoInstitute of Cancer Research, London, United Kingdom. johann.de-bono@icr.ac.uk.
Institute of Cancer Research · GBRoyal Marsden NHS Foundation Trust · GBCornell University · USHebron University · PSUniversity of Bern · CH
Funding
Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate CancerR37CA215040 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BARBIERI, CHRISTOPHER E · 2018 to 2024
$2.6MGenomic instability and DNA repair in a distinct molecular class of prostate cancK08CA187417 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BARBIERI, CHRISTOPHER E · 2014 to 2018
$865kMedical Research Council MR/M018318/1NCI NIH HHS K08 CA187417NCI NIH HHS R37 CA215040Prostate Cancer UK PG13-036
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene DeletionMutationSynthetic Lethal MutationsAgedAndrostenesCell Line, TumorDisease ProgressionDNA-Binding ProteinsDNA HelicasesDrug Resistance, NeoplasmGene ExpressionHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingabirateroneAndrostenesCHD1 protein, humanDNA-Binding ProteinsDNA HelicasesNuclear ProteinsRepressor ProteinsRNA, Small InterferingSPOP protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.